A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis (REGENCY)
Diseases of the Musculoskeletal System | Immune System
What is the purpose of this trial?
The purpose of this study is to compare the effects, good or bad, of Obinutuzumab versus placebo on patients with lupus nephritis. Obinutuzumab is a monoclonal antibody that targets a type of white blood cells known as a B cell and is an approved drug for certain types of blood cancers. This study will help determine if using Obinutuzumab to reduce B cells will improve the signs and symptoms of lupus nephritis. If you meet the study requirements and are enrolled, you will be in this study for about 76 weeks.
- Ages18 years - 75 years
- Trial withGenentech, Inc.
- Start Date09/14/2021
- End Date10/06/2023
- Last Updated10/22/2021
- Study HIC#2000028219